In April 2026, President Trump signed an executive order directing federal agencies to accelerate research and expand patient access to psychedelic-assisted therapies. Within 90 days, that direction had moved toward concrete action.
On July 13, the Department of Health and Human Services and the Department of Veterans Affairs signed a five-year agreement covering clinical research, workforce training, protocol development, and implementation planning – expressly aimed at preparing for the responsible deployment of future FDA-approved rapid-acting treatments for veterans.
Separately, the FDA and HRSA opened input processes on provider qualifications, credentialing, supervision, licensing, and care delivery models. This is not a policy announcement waiting to become real. The federal government is actively building the workforce infrastructure for psychedelic-assisted therapy. The pace has surprised many in the field.
What it hasn’t done is resolve a distortion that was present long before the executive order – and that the order has made it harder to correct. Many of the people in the room on signing day have personal experience with both ibogaine and 5-MeO-DMT. Both compounds have been part of the conversations that led to this moment.
But ibogaine is the one that received a presidential mention, and that spotlight has deepened a misunderstanding that already existed in public discourse: that ibogaine is the compound for treating addiction and trauma, and that 5-MeO-DMT sits somewhere else entirely. It doesn’t.
The therapeutic work being done with 5-MeO-DMT is serious, substantive, and ongoing. It simply isn’t the work that made it into the text of an executive order. That distinction matters – for patients, for policymakers, and especially for practitioners trying to understand what this federal momentum means for their professional preparation.
Federal agencies are beginning to build the workforce and healthcare infrastructure that may support psychedelic-assisted therapy at scale. That is meaningful progress. But the workforce being built has gaps. Understanding those gaps, and what they mean for anyone considering rigorous psychedelic facilitator training right now, is what this piece is about.
What the federal government is actually building
In April 2026, the executive order set the direction. It instructed the FDA and DEA to establish expanded access pathways for eligible patients and to prioritise review of psychedelic compounds already in the clinical pipeline.
It authorised Commissioner’s National Priority Vouchers for compounds receiving Breakthrough Therapy designation. It directed the Attorney General to reschedule compounds that complete Phase 3 trials.
That was the starting point. What has followed is more structural.
On July 13, HHS and the VA signed a five-year Memorandum of Understanding.
The agreement goes beyond research funding. It covers clinical protocol development, workforce training, and implementation planning – all expressly oriented toward the responsible deployment of future FDA-approved rapid-acting treatments for veterans.
This is the federal government committing to build the systems that would actually deliver psychedelic-assisted therapy, not just study it. At the same time, the FDA and HRSA have opened separate input processes. They are gathering perspectives on provider qualifications, credentialing frameworks, supervision models, licensing requirements, and care delivery structures.
These are the questions that determine who is recognised as qualified to do this work – and under what conditions. Taken together, this represents a shift in the nature of the federal conversation. It is no longer only about whether psychedelic compounds work. It is about who delivers them, how those people are trained, and what the professional standard looks like.
That is a consequential change. And it comes with an important clarification.
The executive order does not reschedule any compound. It does not grant FDA approval to any therapy. It does not shorten the Phase 3 clinical trial requirements that any compound must meet before it can be prescribed.
Those processes are moving faster than before – but they are still measured in years, not months. The institutional clock and the professional preparation clock are not the same. Understanding the difference between the two is the starting point for any serious practitioner decision-making right now.
Why the federal workforce model has gaps
The federal infrastructure taking shape is serious and necessary. A five-year HHS-VA agreement, active FDA and HRSA input processes, and a presidential directive to accelerate the field – these are not small developments.
They represent a genuine commitment to building the systems that psychedelic-assisted therapy will require.
But the workforce model being built has a defined scope. And that scope leaves significant ground uncovered.
The HHS-VA framework is clinician-led by design. It is built around licensed healthcare professionals operating within VA and federal health infrastructure – physicians, psychiatrists, and clinical staff preparing to deliver future FDA-approved treatments to veterans.
That is the right framework for that purpose. It is not, however, a framework for the broader facilitator community. The experienced practitioners, integration specialists, peer supporters, and professional guides who deliver the majority of 5-MeO-DMT work today are not the population this agreement is designed to prepare.
The FDA and HRSA input processes are similarly focused. The provider qualification and credentialing questions being asked relate to compounds with existing clinical trial programmes.
5-MeO-DMT-specific competency standards do not yet exist at a federal level. That means the field faces a choice: wait for those standards to be written from the outside, or build the professional frameworks now that will inform what those standards should be.
There is a third gap that the current federal model does not address at all – and it may be the most consequential one for practitioners reading this. When a field moves from the margins toward the mainstream, the standards that apply to it tighten. That is not a threat. It is how professional legitimacy works.
Regulatory attention brings accountability. The practitioners who will be most exposed by that accountability are those doing serious work without serious preparation behind them. An executive order and a five-year federal agreement signal that psychedelic-assisted therapy is being treated as medicine. Medicine has standards. Those standards are coming – and for 5-MeO-DMT, they have not yet been written.
The demand picture reinforces this. Industry analysts project that more than 50,000 therapists will need psychedelic training over the next decade.
That figure relates to the broader psychedelic therapy field – it does not account for the specific competency requirements of 5-MeO-DMT facilitation, which are distinct from psilocybin or MDMA training in ways that matter clinically.
The facilitators investing in rigorous psychedelic facilitator training now are the ones who will be positioned when that demand becomes accessible. The federal workforce model is building something real. It is not building everything the field needs.
That gap is where the work of preparation happens – and it is where the practitioner community has both the most responsibility and the most opportunity right now.
What qualified 5-MeO-DMT facilitator training looks like
Understanding the gap in the federal workforce model is one thing. Knowing what serious preparation actually requires is another. The two questions are connected – because the competency standards that federal agencies will eventually formalise will reflect what rigorous 5-MeO-DMT training already looks like in practice. That practice exists today.
5-MeO-DMT is not a compound that general psychedelic training covers adequately. This is not a matter of opinion – it is a pharmacological reality. The experience profile, the onset and duration, the contraindication set, and the integration requirements are all distinct from psilocybin, MDMA, or ketamine-assisted therapy.
A practitioner trained thoroughly in one does not arrive at the other prepared. The crossover in principle is real. The crossover in practice requires specific, substance-level preparation.
Qualified 5-MeO-DMT facilitator training starts with the science. That means 5-MeO-specific pharmacology and neuroscience – not borrowed frameworks from adjacent compounds, but a grounded understanding of how this substance acts in the human body and what that means for the people being supported.
It means knowing the contraindication profile in detail: the cardiovascular considerations, the medication interactions, the personal history factors that change the risk picture significantly.
Screening and preparation protocols exist for a reason. They are not administrative procedures. They are clinical safeguards. It means understanding integration as a distinct discipline for 5-MeO-DMT work specifically. The integration requirements following a 5-MeO-DMT experience differ structurally from those following a psilocybin session.
The nature of the experience: its intensity, its non-dual character, the frequency with which it produces what practitioners describe as an ego-dissolution rather than a guided psychological journey, creates integration needs that require a specific framework, not a general one.
Practitioners without that framework are not equipped to support the people in their care through what comes after. It means harm reduction as a professional commitment, not a disclaimer. The field is operating in a legal grey zone that will not resolve quickly, even with federal momentum behind it.
Practitioners who treat harm reduction as a core ethical obligation, who understand the risks clearly and communicate them honestly, are the ones building the professional standard the field will be held to.
And it means understanding the difference between a certificate and a credential. A certificate confirms that someone completed a programme. A credential reflects demonstrated competency, peer recognition, supervised practice, and integration into a professional community.
The federal credentialing frameworks being developed will make that distinction – and the practitioners who have built real credentials, not just completed courses, will be the ones who meet it.
F.I.V.E.’s 9-month facilitator training programme is built on these foundations. The curriculum covers 5-MeO-specific pharmacology, screening and preparation protocols, integration frameworks, harm reduction practice, and ethical facilitation – developed with and for the practitioner community working with this compound.
It is not a general psychedelic training with 5-MeO added. It is a programme built from the ground up around what safe, ethical 5-MeO-DMT facilitation actually requires.
What this moment asks of practitioners
The federal government is asking a question that the psychedelic therapy field has been building toward for years: who is qualified to do this work, and how do we know? The HHS-VA agreement, the FDA and HRSA input processes, the executive order itself – these are all, in different ways, attempts to answer that question at an institutional level.
But institutions answer that question after the fact. The practitioners doing the work now are answering it in real time.
For healthcare professionals and therapists who are new to 5-MeO-DMT, this moment has a specific shape.
The clinical infrastructure for psychedelic-assisted therapy is being built around you – your profession, your licensing frameworks, your existing relationships with patients and clients. The question is not whether this field is becoming relevant to your practice. It is.
The question is whether you engage with it on your own terms, grounded in rigorous preparation, or whether you wait for a credentialing framework to tell you what you should already know. The federal process will eventually produce standards. Those standards will reflect the input of the practitioners, researchers, and training organisations that showed up while they were being written.
Practitioners who are part of that conversation, who have built real competency in 5-MeO-DMT facilitation and can speak to what the professional standard should be, have a different relationship to that process than those who are waiting for its output.
For experienced practitioners already working with 5-MeO-DMT, the moment asks something equally direct. The professionalisation of this field is not a future event. It is happening now. The scrutiny that comes with federal attention is not directed only at bad actors – it applies to the field as a whole.
Practitioners who have built their practice on experience, intention, and personal commitment are doing important work. That work deserves the professional foundation that makes it defensible, sustainable, and safe: for the people being supported, and for the practitioners themselves.
Rigorous training is not a bureaucratic requirement. It is an ethical one.
This is also a community moment. The practitioners training seriously right now are not just preparing themselves – they are helping to define what ethical 5-MeO-DMT facilitation looks like before the regulators do it for them.
The standards that emerge from this period will reflect who participated in building them. F.I.V.E. exists to be part of that: to bring together the practitioners, healthcare professionals, and integration specialists who take this work seriously, and to give that community the preparation and the peer network it needs to do it well.
The field is moving. The infrastructure is being built. The question of who is ready to meet it is being answered right now – one practitioner at a time.
Apply for the 9-month facilitator programme
The next F.I.V.E. cohort opens in September 2026. If you are a healthcare professional, therapist, or experienced practitioner considering serious preparation in 5-MeO-DMT facilitation, applications are open now.